On the basis of univariate marker analyses, we identified 14 and 18 markers with sampling error-robust performance across L and H TMA samples for disease aggressiveness and lethal outcome, respectively (markers with red font in Figure 4).
Kaplan Meier analyses identified 11 markers as being univariate significant factors: AR epithelial/stromal, CB1R, CRGA, E-Cadherin, EZH2, Ki-67, NFkB, p21, p27, and PSMA (Table 2).
The outlier analyses identified a single marker, Adh, with an excessively high FST value compared to neutral expectations.
Microgenomic analyses identified novel transcriptional markers and revealed pathways of muscle fiber plasticity.
Subsequent analyses identified four predictive markers for the French collection that were used for the logistic regression model.
Uni- and multivariate analyses identified PFTK1 as an independent marker of prognosis (RR=2.428, 95% CI=1.615 3.711, P<0.001).
In addition, multivariate analyses identified TRAIL-γ as an independent prognostic marker.
In addition, immunocytochemistry analyses identified cells positive for SRY-box containing gene 17 (SOX17, endoderm marker), α-smooth muscle actin (α-SMA, mesoderm marker), Desmin (mesoderm marker), glial fibrillary alkaline phospatase (GFAP, ectoderm marker) and Tuj1 (ectoderm marker) (Fig. 3a, Figure S7b).
Both univariate and multivariate analyses identified stage (p<0.0001) and LEF1 overexpression (p<0.05) as important prognostic markers, but not tumor grade or SPP1.
These analyses identified two main groups.
